Department of Molecular Sciences, Faculty of Medicine, University of Medicine and Pharmacy "Iuliu Hațieganu", 400012 Cluj-Napoca, Romania.
Regional Laboratory Cluj-Napoca, Department of Medical Genetics, Regina Maria Health Network, 400363 Cluj-Napoca, Romania.
Medicina (Kaunas). 2024 May 6;60(5):767. doi: 10.3390/medicina60050767.
PTEN Hamartoma Tumour Syndrome (PHTS) encompasses diverse clinical phenotypes, including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome (PS), and Proteus-like syndrome. This autosomal dominant genetic predisposition with high penetrance arises from heterozygous germline variants in the PTEN tumour suppressor gene, leading to dysregulation of the PI3K/AKT/mTOR signalling pathway, which promotes the overgrowth of multiple and heterogenous tissue types. Clinical presentations of CS range from benign and malignant disorders, affecting nearly every system within the human body. CS is the most diagnosed syndrome among the PHTS group, notwithstanding its weak incidence (1:200,000), for which it is considered rare, and its precise incidence remains unknown among other important factors. The literature is notably inconsistent in reporting the frequencies and occurrences of these disorders, adding an element of bias and uncertainty when looking back at the available research. In this review, we aimed to highlight the significant disparities found in various studies concerning CS and to review the clinical manifestations encountered in CS patients. Furthermore, we intended to emphasize the great significance of early diagnosis as patients will benefit from a longer lifespan while being unceasingly advised and supported by a multidisciplinary team.
PTEN 错构瘤肿瘤综合征(PHTS)包括多种临床表型,包括考登综合征(CS)、班纳扬-赖利-鲁瓦卡巴综合征(BRRS)、变形杆菌综合征(PS)和变形杆菌样综合征。这种常染色体显性遗传易感性具有高外显率,源于 PTEN 肿瘤抑制基因的杂合种系变异,导致 PI3K/AKT/mTOR 信号通路失调,从而促进多种异质组织类型的过度生长。CS 的临床表现从良性和恶性疾病不等,影响人体几乎每一个系统。CS 是 PHTS 组中诊断最多的综合征,尽管其发病率较低(1:200000),因此被认为是罕见的,其确切发病率在其他重要因素中仍然未知。文献在报告这些疾病的频率和发生情况时存在显著差异,这在回顾现有研究时增加了一定的偏见和不确定性。在这篇综述中,我们旨在强调在 CS 相关的各种研究中发现的显著差异,并回顾 CS 患者的临床表现。此外,我们还强调早期诊断的重要性,因为患者将受益于更长的寿命,同时不断得到多学科团队的建议和支持。